SkyOak Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

SkyOak Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-760	Closed	-$229K	–	241
2026 Q2	$229K	Hold	760	–	–	0.04%	229
2026 Q1	$251K	Hold	760	–	–	0.05%	205
2025 Q4	$302K	Sell	760 -87	-10%	-$38.5K	0.05%	181
2025 Q3	$386K	Buy	+847	New	+$345K	0.07%	150
2021 Q3	–	Sell	-1,681	Closed	-$285K	–	233
2021 Q2	$285K	Sell	1,681 -27	-2%	-$3.95K	0.08%	177
2021 Q1	$245K	Sell	1,708 -1,837	-52%	-$276K	0.07%	192
2020 Q4	$461K	Buy	+3,545	New	+$473K	0.14%	134

Other funds holding ALNY

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

SkyOak Wealth's ALNY Position: Q3 2026 in Review

SkyOak Wealth sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2026, closing a stake of 760 shares — an estimated $229K sold.

SkyOak Wealth first reported a position in ALNY in Q4 2020 and held it in 7 quarters. The position peaked at $461K in Q4 2020. 328 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

SkyOak Wealth reported no remaining Alnylam Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
SkyOak Wealth sold 760 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $229K.
SkyOak Wealth first reported a position in Alnylam Pharmaceuticals in Q4 2020 and held it in 7 quarters.
SkyOak Wealth's Alnylam Pharmaceuticals position peaked at $461K in Q4 2020.
328 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on SkyOak Wealth's 13F filing for Q3 2026, filed 28 Oct 2026.